Predictors of Improvement in left ventricular ejection fraction with carvedilol for congestive heart failure

Journal of Nuclear Cardiology

Volumn 7, Issue 1, 2000, Pages 3-7

  O'Keefe Jr , James H ^a,c   Magalski, Anthony ^a   Stevens, Tracy L ^a   Bresnahan Jr , Dennis R ^a   Alaswad, Khaldoon ^a   Krueger, Steven K ^b   Bateman, Timothy M ^a  

^a SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^b Nebraska Heart Hospital   (United States)

^c NONE   (United States)

Author keywords

Carvedilol; Congestive heart failure; Left ventricular function; Radionuclide ventriculography; blocker therapy

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; CARDIOMYOPATHY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; RADIOISOTOPE VENTRICULOGRAPHY; SIDE EFFECT; SURVIVAL;

EID: 0034004536     PISSN: 10713581     EISSN: None     Source Type: Journal    
DOI: 10.1067/mnc.2000.102678     Document Type: Article

References (24)

1. Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol 1997;80:26L-40L.
2. Esler M, Kaye D, Lambert G, Esler D, Jennings G. Adrenergic nervous system in heart failure. Am J Cardiol 1997;80:7L-14L.
3. Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart. Circulation 1996;94:2285-96.
4. Gupta PD, Broadhurst P, Raftery EB, Lahiri A. Value of carvedilol in congestive heart failure secondary to coronary artery disease. Am J Cardiol 1990;66:1118-23.
5. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, et al. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol 1995;25:1225-31.
6. Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J Am Coll Cardiol 1997;29:1060-6.
7. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with β-adrenergic blockade. J Am Coll Cardiol 1995;25:1154-61.
8. Australia/NewZealand Heart Failure Research Collaborative Group. Randomized, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet 1997;349:375-80.
9. Heidenreich PA, Lee TT, Massie BM. Effect of β-blockers on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Cardiol 1997;30:27-34.
10. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect on carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
11. Lowes BD, Gill EA, Abraham WT, Larrain J, Robertson AD, Bristow MR, et al. Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am J Cardiol 1999;83:1201-5.
12. Senior R, Basu S, Kinsey C, Schaeffer S, Lahiri A. Carvedilol prevents remodeling in patients with left ventricular dysfunction after acute myocardial infarction. Am Heart J 1999;137:646-52.
13. Bristow MR, Gilbert EM, Abraham WT, Adams KF, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807-16.
14. Omland T, Bonarjee V, Lie RT, Caidahl K. Neurohumoral measurements as indicators of long-term prognosis after acute myocardial infarction. Am J Cardiol 1995;76:230-5.
15. Cohn JR, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-10.
16. Chalmers JP, West MJ, Cyran J, et al. Placebo-controlled study of lisinopril in congestive heart failure: a multicentre study. J Cardiovasc Pharmacol 1987;9(suppl):S89-S97.
17. Konstam MA, Cody RJ. Short-term use of intravenous milrinone for heart failure. Am J Cardiol 1995;75:822-6.
18. Packer M, Carver JR, Chesebro JH, Ivanhoe RJ, DiBianco R, Zeldis SM, et al. Effect of milrinone on mortality in severe chronic heart failure: the Prospective Randomized Milrinone Survival Evaluation (PROMISE). N Engl J Med 1991;325:1468-75.
19. Packer M, Narahara KA, Elkayam U, Sullivan JM, Pearle DL, Massie BM, et al and the Prinicpal Investigators of the REFLECT Study. Double-blind, placebo-controlled study of the efficacy of fiosequinan in patients with chronic heart failure. J Am Coll Cardiol 1993;22:65-72.
20. Dibianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, Wright R. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 1989;320:677-83.
21. Ewy GA. Inotropic infusions for chronic congestive heart failure: medical miracles or misguided medicinals? J Am Coll Cardiol 1999;33:572-5.
22. Lahiri A, Senior R. Evolving therapeutic concepts and imaging in ischemic cardiomyopathy. J Nucl Cardiol 1998;5:598-608.
23. Macdonald PS, Keogh AM, Aboyoun CL, Lund M, Amor R, McCaffrey DJ. Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure. J Am Coll Cardiol 1999;33:924-31.
24. Le Jemtel TH, Galveo M, Sonnenblick EH. β-adrenergic blockade reverses, while ACE inhibition attenuates, left ventricular remodeling in patients with chronic heart failure. Heart Failure 1998;Spring:57-63.